The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 02, 2018

Filed:

Jul. 12, 2012
Applicants:

Alberto A. Gabizon, Jerusalem, IL;

Yechezkel Barenholz, Jerusalem, IL;

Hilary Shmeeda, Givat Zeev, IL;

John Maher, London, GB;

Ana Catarina Parente Pereira, London, GB;

Inventors:

Alberto A. Gabizon, Jerusalem, IL;

Yechezkel Barenholz, Jerusalem, IL;

Hilary Shmeeda, Givat Zeev, IL;

John Maher, London, GB;

Ana Catarina Parente Pereira, London, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/704 (2006.01); A61K 9/127 (2006.01); A61K 31/663 (2006.01); A61K 38/20 (2006.01); A61K 45/06 (2006.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61K 47/55 (2017.01); A61K 47/69 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 9/1278 (2013.01); A61K 31/663 (2013.01); A61K 31/704 (2013.01); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 38/2013 (2013.01); A61K 38/2026 (2013.01); A61K 38/2086 (2013.01); A61K 45/06 (2013.01); A61K 47/551 (2017.08); A61K 47/6911 (2017.08); A61K 2039/5158 (2013.01); A61K 2039/55555 (2013.01);
Abstract

The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as γδ T-cells.


Find Patent Forward Citations

Loading…